New pill aims to keep depression away longer
NCT ID NCT07196501
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tests whether adding NBI-1065845 to standard antidepressants can delay the return of depressive symptoms in adults with major depression. About 550 people who have not fully responded to current antidepressants will take either the study drug or a placebo pill. The main goal is to see how long it takes for depression symptoms to come back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-1065845 (oral tablet)
What this could lead to
If it works, this could provide a new add-on option to help people with major depression stay well longer and delay relapse.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to everyone with depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGOceanside, California, 92056, United States
-
Neurocrine Clinical Site
RECRUITINGSan Jose, California, 95124, United States
-
Neurocrine Clinical Site
RECRUITINGNew Haven, Connecticut, 06520, United States
-
Neurocrine Clinical Site
RECRUITINGMiami Gardens, Florida, 33014, United States
-
Neurocrine Clinical Site
RECRUITINGOrlando, Florida, 32803, United States
-
Neurocrine Clinical Site
RECRUITINGPalm Bay, Florida, 32905, United States
-
Neurocrine Clinical Site
RECRUITINGTampa, Florida, 33629, United States
-
Neurocrine Clinical Site
RECRUITINGMarrero, Louisiana, 70072, United States
-
Neurocrine Clinical Site
RECRUITINGO'Fallon, Missouri, 63368, United States
-
Neurocrine Clinical Site
RECRUITINGAlbuquerque, New Mexico, 87109, United States
-
Neurocrine Clinical Site
RECRUITINGCharlotte, North Carolina, 28211, United States
-
Neurocrine Clinical Site
RECRUITINGEdmond, Oklahoma, 73013, United States
-
Neurocrine Clinical Site
RECRUITINGOklahoma City, Oklahoma, 73112, United States
-
Neurocrine Clinical Site
RECRUITINGBellaire, Texas, 77401, United States
-
Neurocrine Clinical Site
RECRUITINGFriendswood, Texas, 77546, United States
-
Neurocrine Clinical Site
RECRUITINGStafford, Texas, 77477, United States
-
Neurocrine Clinical Site
RECRUITINGWichita Falls, Texas, 76309, United States
-
Neurocrine Clinical Site
RECRUITINGDraper, Utah, 84020, United States
-
Neurocrine Clinical Site
RECRUITINGCarlton, Victoria, 3053, Australia
-
Neurocrine Clinical Site
RECRUITINGSofia, 1303, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGSofia, 1408, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGSofia, 1510, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGSofia, 1680, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGNorth Vancouver, British Columbia, V7P 2T4, Canada
-
Neurocrine Clinical Site
RECRUITINGSherbrooke, Quebec, J1L 0H8, Canada
-
Neurocrine Clinical Site
RECRUITINGToronto, M5H 1A1, Canada
-
Neurocrine Clinical Site
RECRUITINGTallinn, 10138, Estonia
-
Neurocrine Clinical Site
RECRUITINGTallinn, 11315, Estonia
-
Neurocrine Clinical Site
RECRUITINGTartu, 50417, Estonia
-
Neurocrine Clinical Site
RECRUITINGMilan, 20127, Italy
-
Neurocrine Clinical Site
RECRUITINGRome, 168, Italy
-
Neurocrine Clinical Site
RECRUITINGBialystok, 15-879, Poland
-
Neurocrine Clinical Site
RECRUITINGBydgoszcz, 85-794, Poland
-
Neurocrine Clinical Site
RECRUITINGGdansk, 80-283, Poland
-
Neurocrine Clinical Site
RECRUITINGBelgrade, 11000, Serbia
-
Neurocrine Clinical Site
RECRUITINGKovin, 26220, Serbia
-
Neurocrine Clinical Site
RECRUITINGAnsan-si, Gyeonggi-do, 15355, South Korea
-
Neurocrine Clinical Site
RECRUITINGSeoul, 02841, South Korea
-
Neurocrine Clinical Site
RECRUITINGSeoul, 06351, South Korea
-
Neurocrine Clinical Site
RECRUITINGAlcorcón, Madrid, 28922, Spain
-
Neurocrine Clinical Site
RECRUITINGBarcelona, 08035, Spain
-
Neurocrine Clinical Site
RECRUITINGKeelung, 204, Taiwan
-
Neurocrine Clinical Site
RECRUITINGTaipei, 10449, Taiwan
-
Neurocrine Clinical Site
RECRUITINGTaipei, 110, Taiwan
-
Neurocrine Clinical Site
RECRUITINGTaipei, 11217, Taiwan